PRESS RELEASES
GENERAL
Chinese Pharma Licenses Two Drugs
A Chinese pharmaceutical company is licensing two experimental drugs from two University of Texas research institutions for an initial $4.5 million upfront payment.
ALMB-0166
Clinical Trial Approval in Australia.
ALMB-0166 has obtained approval from Australia for conducting the first-in-human clinical trial for the treatment of acute spinal cord injury.
Submission of Clinical Trial Application in Australia
ALMB-0166 is a First-in-Class humanized antibody against a novel target hemichannel composed of Cx43 membrane protein.
Orphan-Drug Designation by the U.S. FDA
This orphan-drug designation will allow the Group to communicate with the U.S. FDA frequently and speed up the clinical development, registration
ALMB-0168
Clinical Trial Approval in Australia
ALMB-0168 has obtained approval from Australia for conducting the first-in-human clinical trial for the treatment of bone cancer and cancer bone metastasis.
Submission of Clinical Trial Application in Australia
ALMB-0168 has been granted orphan-drug designation and rare pediatric disease designation by the U.S. FDA in 2019 for the
ALMB-0168 Granted Rare Pediatric Disease Designation
ALMB-0168 was granted Rare Pediatric Disease Designation by the U.S. FDA
FIRST-IN-CLASS PRODUCT CANDIDATE ALMB-0168
ALMB-0168 was granted Orphan-Drug Designation by the U.S. FDA
AlaMab would welcome the opportunity to discuss possible investment or partnering opportunities.